R&G PharmaStudies - Public Comps and Valuation Multiples

R&G PharmaStudies Overview

About R&G PharmaStudies

R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.

Founded

2008

HQ

Employees

n/a

Website

rg-pharma.com

Sectors

Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $109M

LTM EBITDA $25.7M

EV

$508M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

R&G PharmaStudies Financials

As of November 2025, R&G PharmaStudies reported last 12-month revenue of $109M and EBITDA of $25.7M.

In the same period, R&G PharmaStudies generated $40.2M in LTM gross profit and $19.5M in net income.

See R&G PharmaStudies valuation multiples based on analyst estimates

R&G PharmaStudies P&L

In the most recent fiscal year, R&G PharmaStudies reported revenue of $105M and EBITDA of $27.9M.

R&G PharmaStudies expects next 12-month revenue of XXX and NTM EBITDA of XXX

See R&G PharmaStudies valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$109M	XXX	$105M	XXX	XXX	XXX
Gross Profit	$40.2M	XXX	$39.0M	XXX	XXX	XXX
Gross Margin	37%	XXX	37%	XXX	XXX	XXX
EBITDA	$25.7M	XXX	$27.9M	XXX	XXX	XXX
EBITDA Margin	24%	XXX	27%	XXX	XXX	XXX
EBIT	$21.9M	XXX	$18.5M	XXX	XXX	XXX
EBIT Margin	20%	XXX	18%	XXX	XXX	XXX
Net Profit	$19.5M	XXX	$19.8M	XXX	XXX	XXX
Net Margin	18%	XXX	19%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for R&G PharmaStudies including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $109M. EBITDA for the last twelve months was $25.7M. In the most recent fiscal year, R&G PharmaStudies achieved $105M in revenue and $27.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$109M	Analyst estimates available to subscribers	$105M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$40.2M	Analyst estimates available to subscribers	$39.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	36.8% gross margin	Analyst estimates available to subscribers	37.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$25.7M	Analyst estimates available to subscribers	$27.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.6% EBITDA margin	Analyst estimates available to subscribers	26.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$21.9M	Analyst estimates available to subscribers	$18.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	20.1% EBIT margin	Analyst estimates available to subscribers	17.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$19.5M	Analyst estimates available to subscribers	$19.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	17.9% net profit margin	Analyst estimates available to subscribers	18.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for R&G PharmaStudies

This financial data table provides comprehensive performance metrics for R&G PharmaStudies, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

R&G PharmaStudies generated $109M in revenue over the last twelve months.
The company achieved $25.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $40.2M.
Net income over the last twelve months reached $19.5M.

Fiscal Year Performance

In the most recent fiscal year, R&G PharmaStudies reported $105M in total revenue.
Fiscal year EBITDA was $27.9M.
The company maintained a gross profit margin of 37.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.6%.
Net profit margin reached 18.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for R&G PharmaStudies. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

R&G PharmaStudies Stock Performance

R&G PharmaStudies has current market cap of CNY 5.3B (or $745M), and EV of CNY 3.6B (or $508M).

Market Cap Evolution

R&G PharmaStudies Stock Data

As of December 4, 2025, R&G PharmaStudies's stock price is CNY 55 (or $8).

See R&G PharmaStudies trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$508M	$745M	XXX	XXX	XXX	XXX	$0.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

R&G PharmaStudies Valuation Multiples

R&G PharmaStudies's trades at 4.8x EV/Revenue multiple, and 18.2x EV/EBITDA.

See valuation multiples for R&G PharmaStudies and 15K+ public comps

R&G PharmaStudies Financial Valuation Multiples

As of December 4, 2025, R&G PharmaStudies has market cap of $745M and EV of $508M.

Equity research analysts estimate R&G PharmaStudies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

R&G PharmaStudies has a P/E ratio of 38.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$745M	XXX	$745M	XXX	XXX	XXX
EV (current)	$508M	XXX	$508M	XXX	XXX	XXX
EV/Revenue	4.6x	XXX	4.8x	XXX	XXX	XXX
EV/EBITDA	19.7x	XXX	18.2x	XXX	XXX	XXX
EV/EBIT	23.2x	XXX	27.5x	XXX	XXX	XXX
EV/Gross Profit	12.6x	XXX	n/a	XXX	XXX	XXX
P/E	38.2x	XXX	37.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	26.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get R&G PharmaStudies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

R&G PharmaStudies Margins & Growth Rates

R&G PharmaStudies's last 12 month revenue growth is 10%

R&G PharmaStudies's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

R&G PharmaStudies's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

R&G PharmaStudies's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for R&G PharmaStudies and other 15K+ public comps

R&G PharmaStudies Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	27%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	-8%	XXX	XXX	XXX
Rule of 40	40%	XXX	36%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	48%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	20%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial